Meadow Creek Investment Management’s Acorda Therapeutics ACOR Stock Holding History

Meadow Creek Investment Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-95	Closed	-$87K	–	1392
2019 Q2	$87K	Buy	95 +22	+30%	+$27K	﹤0.01%	1234
2019 Q1	$116K	Hold	73	–	–	﹤0.01%	1157
2018 Q4	$136K	Hold	73	–	–	﹤0.01%	1081
2018 Q3	$172K	Hold	73	–	–	﹤0.01%	1115
2018 Q2	$251K	Hold	73	–	–	0.01%	919
2018 Q1	$207K	Hold	73	–	–	﹤0.01%	982
2017 Q4	$187K	Buy	73 +26	+55%	+$73.9K	﹤0.01%	1019
2017 Q3	$132K	Buy	47 +8	+21%	+$21.1K	﹤0.01%	1068
2017 Q2	$91K	Buy	39 +19	+95%	+$37.6K	﹤0.01%	1133
2017 Q1	$51K	Buy	20 +1	+5%	+$2.88K	﹤0.01%	1157
2016 Q4	$43K	Buy	+19	New	+$45.2K	﹤0.01%	1167

Other funds holding ACOR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meadow Creek Investment Management's ACOR Position: Q3 2019 in Review

Meadow Creek Investment Management sold out of Acorda Therapeutics (ACOR) in Q3 2019, closing a stake of 95 shares — an estimated $87K sold.

Meadow Creek Investment Management first reported a position in ACOR in Q4 2016 and held it in 11 quarters. The position peaked at $251K in Q2 2018. 151 funds tracked by Wall St. Rank hold ACOR as of Q3 2019.

Meadow Creek Investment Management reported no remaining Acorda Therapeutics position as of Q3 2019 after selling out during the quarter.
Meadow Creek Investment Management sold 95 Acorda Therapeutics shares in Q3 2019, an estimated $87K.
Meadow Creek Investment Management first reported a position in Acorda Therapeutics in Q4 2016 and held it in 11 quarters.
Meadow Creek Investment Management's Acorda Therapeutics position peaked at $251K in Q2 2018.
151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.